Gilead's (GILD -2.70%) controversially high priced drug Sovaldi has seen a big pushback against its price point recently, but it seems as though fears of how it would perform in terms of sales were overblown. In its first 12 weeks on the market, the adoption rates already seem monstrous, with 33,672 prescriptions for the drug being filled in that time.
In this video, Motley Fool health-care analyst David Williamson discusses the sales numbers for Sovaldi and why it looks like the greatest drug launch of all time. He also addresses the fear that some have raised, that sales could peak early and then fall off hard thereafter; David tells investors why he doesn't think this is going to be a concern.
